Altacor, a Cambridge, UK-based ophthalmic specialty pharmaceutical company, has closed a £1.9m second tranche of a £3.4m round.
This tranche was led by NVM Private Equity, with participation from Enterprise Ventures and Beringea.
The company intends to use the funds to accelerate both sales and product development activities.
In order to extend its international reach, it is progressing opportunities with third parties including world-wide in-licensing of products and sales and marketing partnerships.
Launched in 2007 and led by CEO Dr Fran Crawford, Altacor develops and markets products in sub therapeutic areas including ocular surface disease, ocular anti-infective and glaucoma.
The company is currently building a portfolio of differentiated ophthalmic products to be launched over the short to medium term in addition to the already marketed Clinitas range of treatments for Dry Eye. Altacor is also pursuing a number of its own proprietary development projects, principally in glaucoma and ocular infection.